ClinicalTrials.Veeva

Find clinical trials for Multiple Sclerosis (MS) in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Warszawa, Mazowieckie, POL:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Drug: Siponimod
Drug: Ofatumumab

Phase 3

Novartis
Novartis

Warsaw, Poland and 72 other locations

This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily o...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis (RRMS)
Drug: IMU-838 (10 mg/day)
Drug: Placebo

Phase 2

Immunic Therapeutics

Warszawa, Poland and 37 other locations

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Enrolling
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Warsaw, Poland and 36 other locations

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Warszawa, Poland and 161 other locations

purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses of RO7121932 in participants with multiple...

Enrolling
Multiple Sclerosis
Drug: RO7121932

Phase 1

Roche
Roche

Warszawa, Poland and 23 other locations

effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...

Active, not recruiting
Multiple Sclerosis
Drug: Beta-Interferon
Drug: Methylprednisolone

Phase 3

Genzyme
Genzyme

Warszawa, Poland and 20 other locations

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a durat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Other: Fingolimod Placebo

Phase 3

Roche
Roche

Warszawa, Poland and 115 other locations

The aim of this protocol is to find out about the safety and effectiveness of M2951 in participants with relapsing multiple sclerosis...

Active, not recruiting
Relapsing-remitting Multiple Sclerosis
Drug: Evobrutinib
Drug: Placebo

Phase 2

Merck KGaA (EMD Serono)
Merck KGaA (EMD Serono)

Warszawa, Poland and 55 other locations

The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: dimethyl fumarate
Drug: Interferon β-1a

Phase 3

Biogen
Biogen

Warsaw, Poland and 61 other locations

Locations recently updated

The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Warszawa, Poland and 70 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems